Windtree Therapeutics

NASDAQ: WINT is a cardiovascular and oncology drug development company. Lead candidate, istaroxime, a Phase 2 molecule with FDA fast track designation being developed as a first-in-class treatment for acute heart failure and cardiogenic shock